MF Researcher Database

Researchers Database

Advance

TYOU Ka

  • Faculty of Medicine
  • School of Medicine
  • Assistant Professor
Last Updated :2026/06/24

Researcher Information

J-Global ID

Research Interests

  • 遺伝子治療   遺伝子診断   泌尿器悪性腫瘍   Gene therapy   Genetic diagnosis   Urogenital malignancy   

Research Areas

  • Life sciences / Urology

Academic & Professional Experience

  • 2008/04 - Today  香川大学医学部泌尿器科学,助教
  • 2007 - 2008  Kagawa UniversityFaculty of Medicine
  • 2005 - 2008  香川産業支援財団希少糖研究センター, 研究員
  • 2002 - 2005  Kagawa UniversityFaculty of Medicine
  • 1992 - 2002  本渓鋼鉄公司衛校附属医院, 講師
  • 1991 - 1992  中国人民解放軍総医院, 研修医
  • 1989 - 1991  本渓鋼鉄公司衛校附属医院, 医師

Education

  •        - 2002  Kagawa Medical University  環境生態系
  •        - 1989  錦州医学院

Association Memberships

  • 日本癌学会   

Published Papers

Conference Activities & Talks

  • Case of Juxtaglomerular cell tumor (Reninoma) of the kidney treated with laparoscopic partial nephrectomy.  [Not invited]
    12th Congress of the Asian Association of Endocrine Surgeons  2010
  • EFFECT OF A PHYTOTHERAPEUTIC AGENT ON STROMA TO EPITHELIAL RATIO, MACROPHAGE INFILTRATION, MIC-1 EXPRESSION, AND CYTOKINE PRODUCTION IN A RATNONBACTERIAL INFLAMMATION MODEL INDUCED BY 17β ESTRADIOL.  [Not invited]
    第3回前立腺生物学シンポジウム 伊勢志摩  2010
  • Case of Juxtaglomerular cell tumor (Reninoma) of the kidney treated with laparoscopic partial nephrectomy.  [Not invited]
    12th Congress of the Asian Association of Endocrine Surgeons  2010
  • EFFECT OF A PHYTOTHERAPEUTIC AGENT ON STROMA TO EPITHELIAL RATIO, MACROPHAGE INFILTRATION, MIC-1 EXPRESSION, AND CYTOKINE PRODUCTION IN A RATNONBACTERIAL INFLAMMATION MODEL INDUCED BY 17β ESTRADIOL.  [Not invited]
    第3回前立腺生物学シンポジウム 伊勢志摩  2010
  • Eviprostatは前立腺腺細胞を保護するか？―Macrophage Inhibitory Cytokine-1(MIC-1)レベルの解析―.  [Not invited]
    第16回日本排尿機能学会  2009
  • Eviprostatは前立腺腺細胞を保護するか？―Macrophage Inhibitory Cytokine-1(MIC-1)レベルの解析―.  [Not invited]
    第16回日本排尿機能学会  2009

MISC

  • 腎細胞癌に対する希少糖D-アロースの増殖阻害作用(Growth Inhibitory Effect of Rare Sugar D-allose on Renal Cell Carcinoma)
    松岡 祐貴; 田岡 利宜也; 張 霞; 杉元 幹史; 筧 善行  西日本泌尿器科  81-  (増刊)  135  -135  2019/10
  • 腎細胞癌に対する希少糖D-アロースの増殖阻害作用(Growth Inhibitory Effect of Rare Sugar D-allose on Renal Cell Carcinoma)
    松岡 祐貴; 田岡 利宜也; 張 霞; 杉元 幹史; 筧 善行  西日本泌尿器科  81-  (増刊)  135  -135  2019/10
  • 希少糖D-alloseが誘導する腎細胞癌に対する抗腫瘍効果
    松岡 祐貴; 小橋口 佳な; 三浦 高慶; 土肥 洋一郎; 宮内 康行; 加藤 琢磨; 張 霞; 田岡 利宜也; 常森 寛行; 上田 修史; 杉元 幹史; 筧 善行  日本癌治療学会学術集会抄録集  57回-  P37  -6  2019/10
  • 温蒸留水による低浸透圧性ストレスは膀胱癌細胞に対して殺細胞効果を発揮する
    松岡 祐貴; 田岡 利宜也; 張 霞; 内藤 宏仁; 宮内 康行; 田島 基史; 加藤 琢磨; 常森 寛行; 上田 修史; 杉元 幹史; 筧 善行  日本癌治療学会学術集会抄録集  56回-  P35  -5  2018/10
  • 膀胱がんにおけるRRM1抑制アデノウィルスベクターの抗腫瘍効果およびGEM耐性の克服(Adenoviral shRNA vector targeting RRM1 has a antitumor activity and overcomes GEM resistance on bladder carcinomas)
    張 霞; 劉 大革; 田岡 利宜也; 杉元 幹史; 筧 善行  日本癌学会総会記事  77回-  1672  -1672  2018/09
  • ヒト膀胱癌細胞株においてPanobinostatはSp抑制を介してGemcitabineと相乗的な抗腫瘍効果を発揮する
    田岡 利宜也; 張 霞; 常森 寛行; 杉元 幹史; 筧 善行  日本癌学会総会記事  75回-  P  -2226  2016/10
  • RRM1高発現膀胱癌細胞株におけるRRM1抑制アデノウィルスベクターの抗細胞増殖効果
    張 霞; 田岡 利宜也; 杉元 幹史; 劉 大革; 筧 善行  日本癌学会総会記事  75回-  P  -3316  2016/10
  • Xia Zhang; Dage Liu; Yushi Hayashida; Homare Okazoe; Takeshi Hashimoto; Nobufumi Ueda; Mikio Sugimoto; Yoshiyuki Kakehi  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES  16-  (10)  24319  -24331  2015/10  [Refereed]
  • Tokunaga Hiryoyasu; LIU Dage; NAKASHIMA Nariyasu; Zhang Xia; NII Kazuhito; GO Tetsuhiko; HUANG Cheng-long; YOKOMISE Hiroyasu  Eur J Cancer  51-  (16)  2480-9  -9  2015/09  [Refereed]
  • KAZUHITO NII; YOSHIMASA TOKUNAGA; DAGE LIU; XIA ZHANG; JUN NAKANO; SHINYA ISHIKAWA; YOSHIYUKI KAKEHI; REIJI HABA; YOKOMISE HIROYASU  Mol Clin Oncol.  2-  (4)  539-544  2014/07  [Refereed]
  • ラット非細菌性前立腺炎(NBP)モデルにおける、NBP誘発後に投与したEviprostatの効果
    渋谷 信介; 張 霞; 杉元 幹史; 上田 修史; 常森 寛行; 田岡 利宜也; 筧 善行  日本排尿機能学会誌  24-  (1)  242  -242  2013/09
  • Okazoe H; Zhang X; Liu D; Shibuya S; Ueda N; Sugimoto M; Kakehi Y  Int J Mol Sci.  14-  (6)  12367-79  -79  2013/06  [Refereed]
  • Nariyasu Nakashima; Dage Liu; Cheng-long Huang; Masaki Ueno; Xia Zhang; Hiroyasu Yokomise  LUNG CANCER  76-  (2)  228  -234  2012/05  [Refereed]
  • Hiroyuki Tsunemori; Mikio Sugimoto; Zhang Xia; Rikiya Taoka; Xia Zhang; Yoshiyuki Kakehi  UROLOGY  77-  (6)  15-20  2011/06  [Refereed]
  • Eviprostatは前立腺腺細胞を保護するか? Macrophage Inhibitory Cytokine-1(MIC-1)レベルの解析
    杉元 幹史; 張 霞; 常森 寛行; 植月 祐次; 山下 資樹; 乾 政志; 筧 善行  日本排尿機能学会誌  20-  (1)  162  -162  2009/09

Research Grants & Projects

  • Elucidating the antitumor effect of the rare sugar D-allose on renal cell carcinoma
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2024/04 -2027/03 
    Author : 田岡 利宜也; 杉元 幹史; 内藤 宏仁; 張 霞; 松岡 祐貴
  • 薬剤耐性腫瘍に対する標的分子抑制ベクターによる遺伝子治療の開発
    日本学術振興会：科学研究費助成事業 基盤研究(C)
    Date (from‐to) : 2022/04 -2025/03 
    Author : 張 霞
  • Development of a novel treatment strategy for renal cell carcinoma using the rare sugar D-allose: Elucidation of the antitumor mechanism.
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2020/04 -2023/03 
    Author : 田岡 利宜也; 杉元 幹史; 筧 善行; 張 霞; 松岡 祐貴
     
    希少糖は「自然界にその存在量が少ない単糖とその誘導体」と定義され、香川大学は独自技術により、すべての希少糖を生産できる「世界で唯一の研究機関」である。 一方、腎細胞癌は、Glucose Transporter高発現によるD-glucoseの取り込み過多とGlycogenの蓄積を特徴とする癌種で、本開発課題は「希少糖が、高い糖代謝能を有する腎細胞癌に蓄積し、その特異な生理活性が抗腫瘍効果に繋がる」との独創的な着想のもと開始された。 本研究課題が対象とする根治切除不能腎細胞癌は、5年生存率で13.0%と報告されるなど、分子標的薬や免疫チェックポイント阻害剤が導入された現在においても、未だ満足できる治療アウトカムに達しておらず、新規治療薬を用いた治療戦略の構築は喫緊のunmet-needsである。 現在までに本研究課題は、希少糖生産で基本構造体となる11種類の希少糖のうちD-alloseが腎細胞癌に対し最も強い抗腫瘍効果を発揮すること、そしてD-alloseが泌尿器癌（腎細胞癌、膀胱癌、前立腺癌）のうち腎細胞癌で最も多く取り込まれ、かつ低濃度から抗腫瘍効果を発揮することを明らかとし、続いて実施した腎細胞癌細胞を用いたXenograft mice modelの経口投与実験においても、D-alloseが腫瘍組織へ移行し、かつ抗腫瘍効果を発揮することを証明した。 現在、本研究課題は遺伝子発現プロファイル解析の結果を基盤とし、D-alloseの腎細胞癌に対する抗腫瘍メカニズム・癌細胞内への取り込みメカニズムの解明に取り組むとと共に、D-alloseの経口投与の成果を基に、将来の臨床応用を目的とした前臨床研究の準備を開始している。
  • Comprehensive analysis of cytokine and chemokine in prostatic hypertrophy with non-bacterial chronic inflammation
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2014/04 -2017/03 
    Author : Sugimoto Mikio
     
    We elucidated that some chemokines, including CCL2/MCP-1 and CXCL1/CINC-1, were elevated in the prostate and urine of non-bacterial prostatitis(NBP) model rats, and Eviprostat potently suppressed the increases in CCL2/MCP-1 and CXCL1/CINC-1. These chemokines are therefore candidate diagnostic biomarkers for nonbacterial chronic prostatic inflammation. However, in human urine, we could not detect the change of chemokines. Further study for detection in human urine is warranted.
  • Anti-proliferative activity of Adenoviral vector expressing short hairpin RNA targeting G-Protein coupled receptor (GPR87) in urothelial carcinoma
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2013/04 -2016/03 
    Author : zhang xia; Sugimoto Mikio; Kakehi Yoshiyuki; Liu Dage; Hayashita Yushi; Hirama Hiromi
     
    GPR87 is a newly deorphanized member of the cell surface molecule G protein-coupled receptor family. GPR signaling was shown to play a role in promotion of cell growth and survival, metastasis, and drug resistance. To explore effective gene therapies for GPR87-expressing cancers including urothelial cancer, we constructed an adenoviral vector expressing short hairpin RNA targeting GPR87 (Ad-shGPR87). We found that Ad-shGPR87 effectively inhibited the proliferation of GPR87-expressing cell lines both in vitro and in vivo. With this effective tool, we then analyzed the intracellular pathways to uncover the mechanism by which GPR87 is able to regulate the proliferation and survival of human bladder cancer cells. Further, knockdown of GPR87 led to a p53-dependent signal transduction and caused apoptosis in the bladder cancer cells. Consequently, GPR87 appeared to be a promising target for gene therapy. These results of were adopted by domestic and international conferences.
  • Study on the usefulness of p2PSA as a predictor of clinical progression in prostate cancer patients undergoing active surveillance
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2012/04 -2015/03 
    Author : KAKEHI Yoshiyuki; SUGIMOTO Mikio; TYOU Ka; HIRAMA Hiromi
     
    In the Japanese multicenter study cohort (the 1st cohort of this project), predictive value of serum p2PSA-related indices and other clinicopathological features at the time of starting active surveillance (AS) for the pathological reclassification at 1 year re-biopsy were investigated. By multivariate logistic regression analysis, baseline %p2PSA and ‘Phi (the Prostate Health Index)’ were the only independent predictive factors for pathological upgrade at 1 year after AS commencement. In the PRIAS-JAPAN study cohort (the 2nd cohort of this project), longitudinally stored frozen sera are under collection from patients who are newly enrolled at 25 institutions where the Institutional Review Board approved the accompanying study. The 1st analysis on the predictive value of %p2PSA and Phi for pathological reclassification is scheduled to be carried out after collection of sera from 200 patients (projected time: the end of 2015).
  • Development of detecting circulating renal cancer cells that have Death Receptor 5 as a surface marker
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2011 -2013 
    Author : HIRAMA Hiromi; KAKEHI Yoshiyuki; SUGIMOTO Mikio; ZHANG Xia
     
    This research was planned with the objective of detecting cancer cells at extremely low volumes circulating in the blood of renal cell carcinoma patients (circulating tumor cells (CTC) in peripheral blood), using fluorescence-labeled antibodies for DR-5, a surface marker of renal cancer cells. In a preliminary experiment, it was possible to count renal cancer cells as CTC. However, in the peripheral blood of localized and metastatic renal cell carcinoma patients (respectively 15 and 4 patients), the positive detection rate for DR-5 was low, and CTC detection was difficult. Moreover, CTC measurement using the blood in the renal veins that first flowed from the kidneys was performed for 13 patients, but there was significant contamination given that this was subsequent to renal excision, and it was found to be unsuitable for CTC measurement.
  • Uroplakin III-delta 4 as a new molecular marker for interstitial cystitis
    Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2009 -2011 
    Author : KAKEHI Yoshiyuki; TYOU Ka; WU Xiu-xian; INUI Masashi; SUGIMOTO Mikio; HONMA Yukio; YOSHIKI Tatsuhiro
     
    Interstitial cystitis(IC) is a chronic bladder disorder affecting approximately one million people in the United States, of whom some 90% are women. IC is characterized by urinary frequency, urinary urgency, bladder discomfort or bladder pain in the absence of any identifiable cause, such as bacterial infection. Due to lacking in a reliably objective diagnostic test, IC remains a diagnosis based on symptoms and exclusion criteria. The apical surface of mammalian urothelium is covered by numerous rigid-appearing plaques that contribute to the permeability barrier. Uroplakins(UPs) Ia, Ib, II, and III consist of these plaques by forming heterodimer pairs(UPIa/ UPII and UPIb/ UPIII). UPIII-delta 4(UP3d4) is a splicing variant of UPIII that can be distinguished from UPIII by lacking exon 4. The whole cDNA fragment for human UP3d4 was molecularly cloned by us from a cDNA library constructed from bladder mucosa samples of a patient with vesicoureteral reflux. We investigated gene expression profile of UPs including UP3d4 in bladder mucosa of patients with IC. One of the major findings of the study was that UP3d4 gene was significantly up-regulated in IC samples. What was more striking was that up-regulation of UP3d4 was specifically observed in non-ulcerative type IC bladder samples. The next step of this study project is to investigate protein expression of UP3d4 in bladder urothelial cells of IC patients. For this purpose, we have raised murine monoclonal antibodies against purified UP3d4 protein which was produced by the recombinant DNA technique. Protein expression of UP3d4 was evaluable in 46 IC patients while 27 were not due to epithelial exfoliation. UP3d4 was immunohistochemically positive in 29 of 46 samples(63%). The positive rate was 80%(20/ 25) in non-ulcer type and 43%(9/ 21) in ulcer type IC(p=0. 014). UP3d4 was not detected in any of non-IC bladder mucosa. Patients with positive UP3d4 staining was younger than those with negative staining(mean age : 51. 5 vs 62. 0, p=0. 029). UP3d4 mRNA expression was identified in urine sediment cells from 24%(8/ 33) IC patients ; 18%(3/ 17) in non-ulcer type and 31%(5/ 16) ulcer type. In conclusion, a high UP3d4 protein expression was demonstrated in urothelium of IC, especially non-ulcer type IC. Detection of UP3d4 mRNA was feasible for urine sediment cells. Further exploration is warranted to investigate the potential role of UP3d4 in pathogenesis and diagnosis of IC.
  • Development of new gene therapy using adenoviral vector expressing short hairpin RNA targeting GPR87 (Ad-shGPR87) for urological caners
    Date (from‐to) : 2010
  • Development of new gene therapy using adenoviral vector expressing short hairpin RNA targeting GPR87 (Ad-shGPR87) for urological caners
    Date (from‐to) : 2010
  • 良好な生検所見を有する前立腺がんの臨床的追跡を基盤とした病態に関する研究
    Date (from‐to) : 2000
  • 良好な生検所見を有する前立腺がんの臨床的追跡を基盤とした病態に関する研究
    Date (from‐to) : 2000
  • Study on anti-cancer drug resistance in urological cancer
  • An analysis of watchful waiting for localized prostate cancer with favorable biopsy features
  • Study on anti-cancer drug resistance in urological cancer

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.